Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. reports developments tied to FB102, its proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Recurring updates cover clinical development in celiac disease, non-segmental vitiligo and alopecia areata, including regulatory designations such as Fast Track status in celiac disease.
Company news also includes quarterly and annual financial results, research and development spending tied to FB102, public financing activity, investor meeting participation and Nasdaq-required disclosures for equity inducement awards under its 2020 Inducement Equity Incentive Plan.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Forte Biosciences (NASDAQ: FBRX) reported full-year 2022 results, highlighting ongoing developments for FB-102, expected to enter clinical trials by early 2024. The firm ended 2022 with approximately $41.1 million in cash and 21 million shares outstanding. Notably, R&D expenses decreased from $13.9 million in 2021 to $5.6 million due to the termination of the FB-401 program following unfavorable trial results. General and administrative expenses increased to $8.3 million due to legal expenses. Net losses improved to $13.9 million from $21.7 million in 2021, translating to a loss per share of $0.80.
Forte Biosciences has appointed David Gryska to its Board of Directors. Gryska, with over 30 years of experience in the life sciences sector, previously served as CFO at Incyte and Celgene. His addition aims to enhance the board's expertise as the company focuses on its lead product, FB-102, which targets autoimmune and oncology applications. CEO Paul Wagner expressed enthusiasm about Gryska's contributions toward driving long-term shareholder value. The appointment is part of Forte's strategic efforts to bolster its leadership team.
Forte Biosciences has appointed Dr. Scott Brun, M.D., as a new board member. Dr. Brun brings extensive experience, including roles at AbbVie and as a Senior Advisor at Horizon Therapeutics. His expertise in product development is expected to enhance the company’s strategy for its lead candidate, FB-102, targeting autoimmune disorders. CEO Paul Wagner emphasized the importance of Dr. Brun's role in guiding pipeline development. This leadership change aims to drive long-term value amid ongoing clinical ambitions.
Forte Biosciences, Inc. (NASDAQ: FBRX) reported significant progress with its lead program, FB-102, which is projected to enter clinical trials in late 2023 or early 2024. The company ended Q3 2022 with approximately $44 million in cash. Appointing Dr. Scott Brun to the board strengthens its leadership, as he brings extensive pharmaceutical experience. Q3 operating expenses decreased to $3.4 million from $7.7 million year-over-year, primarily due to the winding down of the FB-401 program. However, net losses were reported at $3.4 million, compared to $7.8 million in Q3 2021.
Camac Partners, LLC, a major shareholder of Forte Biosciences, Inc. (FBRX), has expressed serious concerns regarding the company's management and board decisions. They noted that Forte's shares have plummeted approximately 95% since its IPO, trading at a 40% discount to its cash reserves of $45 million. The board's recent dilutive capital raise is viewed by Camac as self-serving and lacking justification. Camac urges the board to reconsider its capital allocation strategy and return funds to shareholders, threatening potential legal action if governance issues continue.